Autophagy is a host defensive mechanism responsible for eliminating harmful cellular components through lysosomal degradation. Autophagy has been known to either promote or suppress various cancers including colorectal cancer (CRC). KRAS mutation serves as an important predictive marker for epidermal growth factor receptor (EGFR)-targeted therapies in CRC. However, the relationship between autophagy and KRAS mutation in CRC is not well-studied. In this single-centre study, 92 formalin-fixed paraffin-embedded (FFPE) tissues of CRC patients (42 Malaysian Chinese and 50 Indonesian) were collected and KRAS mutational status was determined by quantitative PCR (qPCR) (n=92) while the expression of autophagy effector (p62, LC3A and LC3B) was examined by immunohistochemistry (IHC) (n=48). The outcomes of each were then associated with the clinicopathological variables (n=48). Our findings demonstrated that the female CRC patients have a higher tendency in developing KRAS mutation in the Malaysian Chinese population (p<0.05). Expression of autophagy effector LC3A was highly associated with the tumour grade in CRC (p<0.001) but not with other clinicopathological parameters. Lastly, the survival analysis did not yield a statistically significant outcome. Overall, this small cohort study concluded that KRAS mutation and autophagy effectors are not good prognostic markers for CRC patients.

1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424. https://doi.org/10.3322/caac.21492
2. Keum, N., & Giovannucci, E. (2019). Global burden of colorectal cancer: Emerging trends, risk factors and prevention strategies. Nature Reviews Gastroenterology & Hepatology, 16(12), 713–732. https://doi.org/10.1038/s41575-019-0189-7
3. Sepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W. W., Cushman-Vokoun, A. M., Funkhouser, W. K., Kopetz, S. E., Latham, J. A., Marcucci, G., Nowak, J. A., Ogino, S.,除去, S. R., Ventura, C. B., & American Society for Clinical Oncology. (2017). Molecular biomarkers for the evaluation of colorectal cancer: Guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. Journal of Clinical Oncology, 35(13), 1453–1486. https://doi.org/10.1200/JCO.2016.71.9807
4. Pang, S. W., Awi, N. J., Armon, S., Teow, S. Y., & Yap, H. Y. (2020). Current update of laboratory molecular diagnostics advancement in management of colorectal cancer (CRC). Diagnostics, 10(1), Article 9. https://doi.org/10.3390/diagnostics10010009
5. Porru, M., Pompili, L., Caruso, C., Biroccio, A., & Leonetti, C. (2018). Targeting KRAS in metastatic colorectal cancer: Current strategies and emerging opportunities. Journal of Experimental & Clinical Cancer Research, 37(1), Article 57. https://doi.org/10.1186/s13046-018-0719-1
6. Khan, K., Valeri, N., Dearman, C., Cope, A., Cunningham, D., & Chau, I. (2019). Targeting EGFR pathway in metastatic colorectal cancer—Tumour heterogeneity and convergent evolution. Critical Reviews in Oncology/Hematology, 143, 153–163. https://doi.org/10.1016/j.critrevonc.2019.09.001
7. Arrington, A. K., Heinrich, E. L., Lee, W., Duldulao, M., Patel, S., Garcia-Aguilar, J., & Kim, J. (2012). Prognostic and predictive roles of KRAS mutation in colorectal cancer. International Journal of Molecular Sciences, 13(10), 12153–12168. https://doi.org/10.3390/ijms131012153
8. Kim, J., Do, E. J., Moinova, H., Myung, S. J., Markowitz, S. D., & Contag, C. H. (2017). Molecular imaging of colorectal tumors by targeting colon cancer secreted protein-2 (CCSP-2). Neoplasia, 19(10), 805–816. https://doi.org/10.1016/j.neo.2017.07.008
9. Lièvre, A., Ouine, B., Canet, J., Grandhomme, A., Lamy, A., Sabourin, J. C., Laurent, M., & Di Fiore, F. (2017). Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma. British Journal of Cancer, 117(12), 1819–1827. https://doi.org/10.1038/bjc.2017.360
10. Pang, S. W., Awi, N. J., Yap, H. Y., & Teow, S. Y. (2018). Cell-based assays for evaluation of autophagy in cancers. In Cell culture. IntechOpen. https://doi.org/10.5772/intechopen.79633
11. Mo, S., Dai, W., Xiang, W., Li, Q., Lin, J., Wang, R., Wang, Z., Zhang, L., Cai, G., & San, J. (2019). Prognostic and predictive value of an autophagy-related signature for early relapse in stages I-III colon cancer. Carcinogenesis, 40(7), 861–870. https://doi.org/10.1093/carcin/bgz031
12. Alves, S., Castro, L., Fernandes, M. S., Francisco, R., Castro, P., Priault, M., Chaves, S. R., Seruca, R., Corte-Real, M., & Sousa, M. J. (2015). Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy. Oncotarget, 6(31), 30787–30802. https://doi.org/10.18632/oncotarget.5021
13. Schmitz, K. J., Ademi, C., Bertram, S., Schmid, K. W., & Baba, H. A. (2016). Prognostic relevance of autophagy-related markers LC3, p62/sequestosome 1, Beclin-1 and ULK1 in colorectal cancer patients with respect to KRAS mutational status. World Journal of Surgical Oncology, 14, Article 189. https://doi.org/10.1186/s12957-016-0942-x
14. Andreyev, H. J., Norman, A. R., Cunningham, D., Oates, J. R., & Clarke, P. A. (1998). Kirsten ras mutations in patients with colorectal cancer: The multicenter “RASCAL” study. Journal of the National Cancer Institute, 90(9), 675–684. https://doi.org/10.1093/jnci/90.9.675
15. Andreyev, H. J., Norman, A. R., Cunningham, D., Oates, J. R., Dix, B. R., Iacopetta, B. J., Young, J., Walsh, T., Ward, R., Hawkins, N., Beranen, A., Smith, G., Giacchetti, S., Rey, J. M., Ribic, M., & Clarke, P. A. (2001). Kirsten ras mutations in patients with colorectal cancer: The “RASCAL II” study. British Journal of Cancer, 85(5), 692–696. https://doi.org/10.1054/bjoc.2001.1964
16. Yang, Q., Huo, S., Sui, Y., & Li, Y. (2018). Mutation status and immunohistochemical correlation of KRAS, NRAS, and BRAF in 260 Chinese colorectal and gastric cancers. Frontiers in Oncology, 8, Article 487. https://doi.org/10.3389/fonc.2018.00487
17. Rimbert, J., Tachon, G., Junca, A., Villalva, C., Karayan-Tapon, L., & Tougeron, D. (2018). Association between clinicopathological characteristics and RAS mutation in colorectal cancer. Modern Pathology, 31(3), 517–526. https://doi.org/10.1038/modpathol.2017.143
18. Kim, H., Heo, J., Lee, J., Lee, J., Lim, T., & Park, Y. S. (2016). The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: A retrospective analysis. BMC Cancer, 16, Article 120. https://doi.org/10.1186/s12885-016-2160-5
19. Imamura, Y., Morikawa, T., Liao, X., Lochhead, P., Kuchiba, A., Yamauchi, M., Qian, Z. R., Nishihara, R., Meyerhardt, J. A., Fuchs, C. S., & Ogino, S. (2012). Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clinical Cancer Research, 18(17), 4753–4763. https://doi.org/10.1158/1078-0432.CCR-11-3220
20. Li, W., Liu, Y., Cai, S., & Zhang, X. (2019). Not all mutations of KRAS predict poor prognosis in patients with colorectal cancer. International Journal of Clinical and Experimental Pathology, 12(3), 957–967.
21. Smeby, J., Sveen, A., Merok, M. A., Danielsen, S. A., Eilertsen, I. A., Guren, M. G., Nesbakken, A., & Lothe, R. A. (2018). CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer. Annals of Oncology, 29(5), 1227–1234. https://doi.org/10.1093/annonc/mdy054
22. Cercek, A., Braghiroli, M. I., Chou, J. F., Hechtman, J. F., Kemeny, N., Saltz, L., Capanu, M., & Yaeger, R. (2017). Clinical features and outcomes of patients with colorectal cancers harboring NRAS mutations. Clinical Cancer Research, 23(16), 4753–4760. https://doi.org/10.1158/1078-0432.CCR-17-0205
23. Zheng, HY., Zhang, X. Y., Wang, X. F., & Sun, B. C. (2012). Autophagy enhances the aggressiveness of human colorectal cancer cells and their ability to adapt to apoptotic stimulus. Cancer Biology & Medicine, 9(2), 105–110. https://doi.org/10.3969/j.issn.2095-3941.2012.02.005
24. Koukourakis, M. I., Kalamida, D., Giatromanolaki, A., Zois, C. E., Polychronidis, A., Pouliliou, S., Mitrakas, A., Gatter, K. C., & Harris, A. L. (2015). Autophagosome proteins LC3A, LC3B and LC3C have distinct subcellular distribution kinetics and expression in cancer cell lines. PLoS One, 10(9), e0137675. https://doi.org/10.1371/journal.pone.0137675
25. Mizushima, N., & Yoshimori, T. (2007). How to interpret LC3 immunoblotting. Autophagy, 3(6), 542–545. https://doi.org/10.4161/auto.4600
26. Niklaus, M., Adams, O., Berezowska, S., Zlobec, I., Graber, F., Slotta-Huspenina, J., Nitsche, U., Rosenberg, R., Tschan, M. P., & Langer, R. (2017). Expression analysis of LC3B and p62 indicates intact activated autophagy is associated with an unfavorable prognosis in colon cancer. Oncotarget, 8(33), 54604–54615. https://doi.org/10.18632/oncotarget.17554
27. Nakayama, S., Karasawa, H., Suzuki, T., Yamauchi, A., Furukawa, T., Ozawa, Y., Mizuma, M., Shima, H., Unno, M., & Horii, A. (2017). p62/sequestosome 1 in human colorectal carcinoma as a potent prognostic predictor associated with cell proliferation. Cancer Medicine, 6(6), 1264–1274. https://doi.org/10.1002/cam4.1065
28. Sato, K., Tsuchihara, K., Fujii, S., Sugiyama, M., Hoyano, T., Mimaki, S., Mitsunaga, S., Ochiai, A., & Esumi, H. (2007). Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation. Cancer Research, 67(20), 9677–9684. https://doi.org/10.1158/0008-5472.CAN-07-1466
29. Zhu, L., Wang, Y., He, J., Tang, J., Lv, W., & Hu, J. (2018). Cytoplasmic SQSTM1/p62 accumulation predicates a poor prognosis in patients with malignant tumor. Journal of Cancer, 9(21), 4072–4086. https://doi.org/10.7150/jca.26781